Galsulfase (Naglazyme) [Internet], PMID: 28121110
Lysosomal storage diseases, PMID: 29152458
Galsulfase (Naglazyme®) therapy in infants with mucopolysaccharidosis VI, PMID: 24108527
Galsulfase, PMID: 16521329
Intravenous Enzyme Replacement Therapy in Mucopolysaccharidoses: Clinical Effectiveness and Limitations, PMID: 32340185
Enzyme replacement therapy with galsulfase for mucopolysaccharidosis type VI, PMID: 26943923
Galsulfase: arylsulfatase B, BM 102, recombinant human arylsulfatase B, recombinant human N-acetylgalactosamine-4-sulfatase, rhASB, PMID: 16128602
Enzyme replacement therapy for mucopolysaccharidosis VI: long-term cardiac effects of galsulfase (Naglazyme®) therapy, PMID: 22669363
Mucopolysaccharidosis VI, PMID: 20385007
Comparison of neutralizing antibody assays for receptor binding and enzyme activity of the enzyme replacement therapeutic Naglazyme (galsulfase), PMID: 18709516
Rapid Desensitization for Immediate Hypersensitivity to Galsulfase Therapy in Patients with MPS VI, PMID: 26951141
Development, validation, and clinical implementation of an assay to measure total antibody response to naglazyme (galsulfase), PMID: 18607760
Recommendations for the management of MPS VI: systematic evidence- and consensus-based guidance, PMID: 31142378
Long-term galsulfase enzyme replacement therapy in Taiwanese mucopolysaccharidosis VI patients: A case series, PMID: 27134829
Mucopolysaccharidosis type VI phenotypes-genotypes and antibody response to galsulfase, PMID: 23557332
Reversed papilledema in an MPS VI patient with galsulfase (Naglazyme) therapy, PMID: 18418554
Is premedication a necessity before galsulfase replacement therapy?, PMID: 27346567
Successful desensitization in a type VI mucopolysaccharidosis patient with probable IgE-mediated allergy to galsulfase [Naglazyme], PMID: 23244660
Clinical effectiveness of enzyme replacement therapy with galsulfase in mucopolysaccharidosis type VI treatment: Systematic review, PMID: 30740728
Enzyme replacement therapy with galsulfase in 34 children younger than five years of age with MPS VI, PMID: 23535281
Successful management of difficult infusion-associated reactions in a young patient with mucopolysaccharidosis type VI receiving recombinant human arylsulfatase B (galsulfase [Naglazyme]), PMID: 18250117
Enzyme Replacement Therapy may Affect Blood Immunosuppressant Monitoring, PMID: 32379593
Enzyme replacement therapy initiated in adulthood: Findings from the mucopolysaccharidosis VI Clinical Surveillance Program, PMID: 31324526
The effect of galsulfase enzyme replacement therapy on the growth of patients with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome), PMID: 28457718
Enzyme replacement therapy with galsulfase for mucopolysaccharidosis VI: clinical facts and figures, PMID: 21434527
Enzyme replacement therapy outcomes across the disease spectrum: Findings from the mucopolysaccharidosis VI Clinical Surveillance Program, PMID: 30834539
Therapy for the mucopolysaccharidoses, PMID: 22210671
Home treatment with Elaprase and Naglazyme is safe in patients with mucopolysaccharidoses types II and VI, respectively, PMID: 18923918
Lysosomal storage diseases, PMID: 18720909
Recent Advances in Treatment Approaches of Mucopolysaccharidosis VI, PMID: 21506914
Growth Charts for Individuals with Mucopolysaccharidosis VI (Maroteaux-Lamy Syndrome), PMID: 25518809
A systematic review of new advances in the management of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): focus on galsulfase, PMID: 19851471
Natural history and galsulfase treatment in mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome)--10-year follow-up of patients who previously participated in an MPS VI Survey Study, PMID: 24764221
Enzymes approved for human therapy: indications, mechanisms and adverse effects, PMID: 25648140
Maroteaux-Lamy syndrome (mucopolysaccharidosis type VI): a single dose of galsulfase further reduces urine glycosaminoglycans after hematopoietic stem cell transplantation, PMID: 20800524
Enzyme replacement therapy for the management of the mucopolysaccharidoses, PMID: 20040314
Long-term outcomes of patients with mucopolysaccharidosis VI treated with galsulfase enzyme replacement therapy since infancy, PMID: 33775523
[Enzyme replacement therapy of lysosomal storage diseases], PMID: 21211680
Early initiation of enzyme replacement therapy for the mucopolysaccharidoses, PMID: 24388732
Pharmacodynamics, pharmacokinetics and biodistribution of recombinant human N-acetylgalactosamine 4-sulfatase after 6months of therapy in cats using different IV infusion durations, PMID: 26776148
Thrombocytopenia associated with galsulfase treatment, PMID: 20670992
Current enzyme replacement therapy for the treatment of lysosomal storage diseases, PMID: 19725195
Home treatment of type VI mucopolysaccharidosis (Maroteaux-Lamy syndrome) an alternative at this time of COVID-19 pandemic: A case in Peru, PMID: 33363956
[Management of mucopolysaccharidosis type VI in adults], PMID: 26502669
[Mucopolysaccharidosis type VI: clinical aspects, diagnosis and treatment with enzyme replacement therapy], PMID: 24862809
[Cardiovascular findings and effects of enzyme replacement therapy in patients with mucopolysaccharidosis type VI], PMID: 31582674
Long-term impact of early initiation of enzyme replacement therapy in 34 MPS VI patients: A resurvey study, PMID: 33678523
Mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome) with a predominantly cardiac phenotype, PMID: 21917494
Joint contractures in the absence of inflammation may indicate mucopolysaccharidosis, PMID: 19852785
[Overview of enzyme replacement therapy in mucopolysaccharidosis], PMID: 17546776
For research use only. Not for human or drug use.
